Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective Multicentre Cohort Study of the Prevalence and Clinical Impact of Germline Deleterious Mutations in DNA Repair Genes of Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Trial Profile

Prospective Multicentre Cohort Study of the Prevalence and Clinical Impact of Germline Deleterious Mutations in DNA Repair Genes of Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Feb 2019

At a glance

  • Drugs Abiraterone (Primary) ; Cabazitaxel (Primary) ; Docetaxel (Primary) ; Enzalutamide (Primary) ; Radium 223 chloride (Primary)
  • Indications Prostate cancer
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms PROREPAIR-B
  • Most Recent Events

    • 01 Feb 2019 Status changed from active, no longer recruiting to completed.
    • 31 Aug 2018 Biomarkers information updated
    • 05 Jun 2018 Results of a subanalysis assessing mCRPC outcomes according to BRCA2 status and treatment sequence (n=348) presented at the 54th Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top